HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.

AuthorsMélanie Claps, Sara Cerri, Salvatore Grisanti, Barbara Lazzari, Vittorio Ferrari, Elisa Roca, Paola Perotti, Massimo Terzolo, Sandra Sigala, Alfredo Berruti
JournalEndocrine (Endocrine) Vol. 61 Issue 1 Pg. 169-172 (07 2018) ISSN: 1559-0100 [Electronic] United States
PMID29019062 (Publication Type: Letter)
Chemical References
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Hormonal
  • Mitotane
  • Hydrocortisone
  • Metyrapone
Topics
  • Adrenal Cortex Neoplasms (complications)
  • Adrenocortical Carcinoma (complications)
  • Adult
  • Aged
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Cushing Syndrome (drug therapy, etiology)
  • Drug Therapy, Combination
  • Feasibility Studies
  • Humans
  • Hydrocortisone (urine)
  • Male
  • Metyrapone (therapeutic use)
  • Middle Aged
  • Mitotane (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: